Cancer-associated thromboembolism: could direct-acting oral anticoagulants be a promising therapeutic option? Literature review

Abstract

Cancer-associated thromboembolism (CAT) is usually managed with low-molecular-weight heparins (LMWHs) or vitamin K antagonists (VKAs). The recent data suggest that direct-acting oral anticoagulants (DOACs) might have a role in the management of CAT both in terms of prevention and treatment. The aim of this article is to review the current literature regarding the use of DOACs in patients with cancer.

Keywords

• cancer
• venous thromboembolic event
• cat
• direct oral anticoagulant drugs
• doacs